Personalized Melanoma mRNA Vaccine Simulator

1. Clinical Regimen Arm Adjuvant mRNA+anti-PD-1

2. Somatic Neoantigen Screening 4/5 Selected

3. Molecular Parameters

Tumor Mutational Burden (TMB) 28.4 mut/Mb

PD-L1 Checkpoint Blockade 95%

LNP Uptake & DC Presentation Lymph Node CD8+ Clones Melanoma Lysis

TCR:pMHC Synapse Loupe: High-affinity TCR binding (KD < 100nM) triggers perforin/granzyme degranulation.

Trial Biomarkers & Efficacy Active Telemetry

Neoantigens Formulated 4

Mean MHC-I Affinity 85.5 nM

CD8+ T-Cell Clonal Expansion 14.8x fold

Tumor Clearance Rate 94.2%

3-Year Recurrence-Free Survival (RFS) 78.6%

Benefit Delta vs Monotherapy +32.4%

Kaplan-Meier Recurrence-Free Survival